Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2005 Mar 8;19(2):40–46. doi: 10.1002/jcla.20054

Pleural fluid interferon‐γ and adenosine deaminase levels in tuberculosis pleural effusion: a cost‐effectiveness analysis

SK Sharma 1,✉, Amit Banga 1,2
PMCID: PMC6808038  PMID: 15756707

Abstract

Pleural fluid levels of interferon‐γ (IFN‐γ) and adenosine deaminase (ADA) have been found to be high in patients with tuberculosis (TB). The present study was carried out to compare the diagnostic utility of these two markers and to carry out a cost‐effectiveness analysis of performing IFN‐γ estimation in comparison to ADA. A total of 52 patients with pleural effusion, 35 of which were found to have TB etiology, were prospectively included for estimation of ADA and IFN‐γ levels. The difference in the cost of performing the two diagnostic tests was compared with the cost of the treatment for a patient with TB. Pleural fluid IFN‐γ (median [range]: 2,100 [70–14,000] vs. 3 [0–160]; P<0.001) as well as ADA levels (mean [SD]: 93.1 [62.3] vs 15.4 [8.7]; P<0.001) were significantly higher in patients with TB effusion. Even though IFN‐γ estimation was more sensitive (97.1 vs. 91.4%), the extra cost of IFN‐γ estimation for detecting one patient with TB was found to be equivalent to the cost of a complete course of antituberculosis treatment for six patients. In developing countries, where TB is rampant and cost is a major concern, pleural fluid IFN‐γ estimation does not seem to be a cost‐effective investigation method for differentiating TB from non‐TB pleural effusion. J. Clin. Lab. Anal. 19:40–46, 2005. © 2005 Wiley‐Liss, Inc.

Keywords: biological markers, cytokine, diagnosis, extrapulmonary tuberculosis, paucibacillary tuberculosis

REFERENCES

  • 1. Raviglione M, Luelmo F. Update on the global epidemiology of TB. Curr Issues Public Health 1996;2:192–197. [PubMed] [Google Scholar]
  • 2. World Health Organization (WHO) . Global TB Control Report. Geneva: World Health Organization; 2003. p 1–218. [Google Scholar]
  • 3. Mehta JB, Dutt A, Harvill L, Mathews KM. Epidemiology of extrapulmonary TB. A comparative analysis with pre‐AIDS era. Chest 1991;99:1134–1138. [DOI] [PubMed] [Google Scholar]
  • 4. Escudero Bueno C, Garcia Clemente M, Cuesta Castro B, et al. Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle. Study of 414 patients. Arch Intern Med 1990;150:1190–1194. [DOI] [PubMed] [Google Scholar]
  • 5. Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987;91:106–109. [DOI] [PubMed] [Google Scholar]
  • 6. Poe RH, Israel RH, Utell MJ, Hall WJ, Greenblatt DW, Kallay MC. Sensitivity, specificity, and predictive values of closed pleural biopsy. Arch Intern Med 1984;144:325–328. [PubMed] [Google Scholar]
  • 7. Fischer D, Van der Weyden MB, Snyderman R, et al. A role for adenosine deaminase in human monocyte maturation. J Clin Invest 1976;2:399–407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Piras MA, Gakis C, Budroni M, Andreoni G. Adenosine deaminase activity in pleural effusions: An aid to differential diagnosis. Br Med J 1978;2:1751–1752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Ocana I, Martinex‐Vazquez JMM, Segura RM, Fernandez De Sevilla T, Capdevila JA. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest 1983;84:51–53. [DOI] [PubMed] [Google Scholar]
  • 10. Pettersson T, Ojala K, Weber TH. Adenosine deaminase in the diagnosis of pleural effusions. Acta Med Scand 1984;215:299–304. [DOI] [PubMed] [Google Scholar]
  • 11. Ocana I, Martinez‐Vazquez JM, Ribera E, Segfura RM, Pascual C. Adenosine deaminase activity in the diagnosis of lymphocytic pleural effusions of tuberculous neoplastic and lymphomatous origin. Tubercle 1986;67:141–145. [DOI] [PubMed] [Google Scholar]
  • 12. Strankinga WFM, Nauta JJP, Straub JP, Stam J. Adenosine deaminase activity in tuberculous pleural effusions: a diagnostic test. Tubercle 1987;68:137–140. [DOI] [PubMed] [Google Scholar]
  • 13. Fontan Bueso J, Verca Hernando H, Garia‐Buela JP, Dominguex Juncal L, Martin Eguna MT. Diagnostic value of simultaneous determination of pleural adenosine deaminase and pleural lysozyme/serum lysozyme ratio in pleural effusions. Chest 1988;93:303–307. [DOI] [PubMed] [Google Scholar]
  • 14. Segura RM, Pascual C, Ocana I, et al. Adenosine deaminase in body fluids: a useful diagnostic tool in tuberculosis. Clin Biochem 1989;22:141–148. [DOI] [PubMed] [Google Scholar]
  • 15. Baganha MF, Pego A, Lima MA, Gaspar EV, Cordeiro AR. Serum and pleural adenosine deaminase: correlation with lymphocytic populations. Chest 1990;97:605–610. [DOI] [PubMed] [Google Scholar]
  • 16. Banales JL, Pineda PR, Fitzgerald JM, Rubio H, Selman M, Salazer Lezama M. Adenosine deaminase in the diagnosis of tuberculosis pleural effusions: a report of 218 patients and review of the literature. Chest 1991;99:355–357. [DOI] [PubMed] [Google Scholar]
  • 17. Sharma SK, Suresh V, Mohan A, et al. A prospective study of sensitivity and specificity of adenosine deaminase in the diagnosis of tuberculosis pleural effusion. Indian J Chest Dis Allied Sci 2001;43:149–155. [PubMed] [Google Scholar]
  • 18. Shimokata K, Kawachi H, Kishimoto H, Maeda F, Ito Y. Local cellular immunity in tuberculous pleurisy. Am Rev Respir Dis 1982;126:822–824. [DOI] [PubMed] [Google Scholar]
  • 19. Ribera E, Ocana I, Martinez‐Vazquez JM, Rossell M, Espanol T, Ruibal A. High level of interferon gamma in tuberculous pleural effusion. Chest 1988;93:308–311. [DOI] [PubMed] [Google Scholar]
  • 20. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN‐gamma in tuberculous pleuritis. J Immunol 1990;145:149–154. [PubMed] [Google Scholar]
  • 21. Soderblom T, Nyberg P, Teppo AM, Klockars M, Riska H, Pettersson T. Pleural fluid interferon‐gamma and tumour necrosis factor‐alpha in tuberculous and rheumatoid pleurisy. Eur Respir J 1996;9:1652–1655. [DOI] [PubMed] [Google Scholar]
  • 22. Ogawa K, Koga H, Hirakata Y, Tomono K, Tashiro T, Kohno S. Differential diagnosis of tuberculous pleurisy by measurement of cytokine concentrations in pleural effusion. Tuber Lung Dis 1997;78:29–34. [DOI] [PubMed] [Google Scholar]
  • 23. Wongtim S, Silachamroon U, Ruxrungtham K, et al. Interferon gamma for diagnosing tuberculous pleural effusions. Thorax 1999;54:921–924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Aoki Y, Katoh O, Nakanishi Y, Kuroki S, Yamada H. A comparison study of IFN‐gamma, ADA, and CA125 as the diagnostic parameters in tuberculous pleuritis. Respir Med 1994;88:139–143. [DOI] [PubMed] [Google Scholar]
  • 25. Villena V, Lopez‐Encuentra A, Echave‐Sustaeta J, Martin‐Escribano P, Ortuno‐de‐Solo B, Estenoz‐Alfaro J. Interferon‐gamma in 388 immunocompromised and immunocompetent patients for diagnosing pleural TB. Eur Respir J 1996;9:2635–2639. [DOI] [PubMed] [Google Scholar]
  • 26. Naito T, Ohtsuka M, Ishikawa H, Satoh H, Hasegawa S. Clinical significance of cytokine measurement in pleural effusion. Kekkaku 1997;72:565–572. [PubMed] [Google Scholar]
  • 27. Yamada Y, Nakamura A, Hosoda M, et al. Cytokines in pleural liquid for diagnosis of tuberculous pleurisy. Respir Med 2001;95:577–581. [DOI] [PubMed] [Google Scholar]
  • 28. Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF. The use of adenosine deaminase and interferon‐gamma as diagnostic tools for tuberculous pericarditis. Chest 2002;122:900–905. [DOI] [PubMed] [Google Scholar]
  • 29. Sharma SK, Saha PK, Dixit Y, Siddaramaiah NH, Seth P, Pande JN. HIV seropositivity among adult TB patients in Delhi. Indian J Chest Dis Allied Sci 2000;42:157–160. [PubMed] [Google Scholar]
  • 30. Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. Cytokine polarization in miliary and pleural TB. J Clin Immunol 2002;22:345–352. [DOI] [PubMed] [Google Scholar]
  • 31. Guisti G. Adenosine deaminase. Enzyme 1971;12:1092–1097. [Google Scholar]
  • 32. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009–1021. [DOI] [PubMed] [Google Scholar]
  • 33. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431–440. [DOI] [PubMed] [Google Scholar]
  • 34. Weinstein MC. Theoretically correct cost‐effectiveness analysis. Med Decis Making 1999;19:381–382. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES